Creating early awareness of ways to prevent TB is crucial.
Coordinated efforts are required to advance TB vaccine development.
To Meg, it seemed that many of the presenters felt that, to move forward with TB vaccine development, a coordinated multinational, financial and political sustaining effort is needed. Sanchia added that protocol design and early involvement of epidemiologic experts are key for successful study execution. This was also the focus of FHI Clinical’s plenary discussion, in which we described our four-pronged approach to site feasibility for TB vaccine trials:
- Biosurveillance analytic methodology
- Indicator and attribute scoring
- Epidemiological analysis
- Epidemiological expert assessment
Identifying high TB-burden areas with eligible, treatment-naïve populations is critical to rapid enrollment, enhanced participant diversity and timely completion of TB vaccine trials. However, we are challenged by the simultaneous development and administration of TB preventive therapy (TPT) as well as varying levels of research capacity in these areas. Watch the plenary session recording to learn more about how an approach that engages clinical operations, epidemiology and other experts early, during protocol design, can be more efficient and help ensure the proposed development plan can be implemented within the target populations.
Equitable access to TB preventive care is important.
FHI Clinical’s Global Strategy team aims to promote clinical equity through research and discourse on trial design at the global level, which was reflected in both the FHI Clinical plenary session and abstract presentation. According to Meg, health equity in the care of TB (and many other diseases) was also a popular theme throughout the conference, including in a discussion with Dr. Molebogeng Rangaka, Associate Professor at the Institute of Global Health, University College London called Impact of TPT on Clinical Trial Design. This discussion highlighted the importance of developing TB vaccine trials that help ensure vulnerable populations have access to existing preventive care.
COVID-19 continues to have an effect on TB vaccine research and development.
FHI Clinical is positioned to help TB vaccine research with our extensive footprint in sub-Saharan Africa.
Read more about FHI Clinical’s experience with research in sub-Saharan Africa, as well as our relationships with local networks such as the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), and how we are positioned for successful trials in Africa.